{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:37Z","timestamp":1793371537373,"version":"4.5.0"},"reference-count":59,"publisher":"Portland Press Ltd.","issue":"15","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular complications contribute to the major mortality and morbidity in type 2 diabetes. Diabetic cardiomyopathy (DCM) is increasingly recognized as an important cause of heart failure. EMPA-REG OUTCOME trial has reported that empagliflozin, the sodium-glucose cotransporter 2 inhibitor, exerts cardiovascular benefits on diabetic population. However, the mechanism by which empagliflozin alleviates DCM still remains unclear. In the current study, we investigated the cardiac protective effects of empagliflozin on spontaneous type 2 diabetic db\/db mice and its potential mechanism. Eight weeks of empagliflozin treatment (10 mg\/kg\/day) decreased body weight and blood glucose level, and increased urinary glucose excretion (UGE) in diabetic mice. Echocardiography revealed that both systolic and diastolic functions of db\/db mice were also obviously improved by empagliflozin. Furthermore, empagliflozin-treated diabetic mice presented with amelioration of cardiac hypertrophy and fibrosis. In addition, diabetic hearts exhibited the deterioration of oxidative stress, apoptosis and pyroptosis, while these effects were significantly counteracted after empagliflozin treatment. Moreover, empagliflozin rescued diabetes-induced suppression of sGC (soluble guanylate cyclase enzyme)-cGMP (cyclic guanosine monophosphate)-PKG (cGMP-dependent protein kinase) pathway. However, when sGC-\u03b2 expression of hearts was inhibited by transvascular delivery of small interfering RNA, cardiac dysfunction was aggravated and the advantages of empagliflozin were reversed through inhibiting sGC-cGMP-PKG pathway. Collectively, these findings indicate that empagliflozin improves cardiac function involving the inhibition of oxidative stress-induced injury via sGC-cGMP-PKG pathway and may be a promising therapeutic option for DCM.<\/jats:p>","DOI":"10.1042\/cs20190585","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T11:56:13Z","timestamp":1563882973000},"page":"1705-1720","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice"],"prefix":"10.1042","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-855X","authenticated-orcid":false,"given":"Mei","family":"Xue","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Chang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhong","family":"Lu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Liu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxin","family":"Xu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Yu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Sun","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"2021113012313212400_B1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2021113012313212400_B2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrcardio.2010.35","article-title":"Intensive glycemic control and cardiovascular disease: an update","volume":"7","author":"Brown","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"2021113012313212400_B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1475-2840-10-29","article-title":"Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community","volume":"10","author":"Somaratne","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113012313212400_B4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113012313212400_B5","doi-asserted-by":"publisher","first-page":"5702103","DOI":"10.1155\/2018\/5702103","article-title":"NLRP3: a novel mediator in cardiovascular disease","volume":"2018","author":"Zhou","year":"2018","journal-title":"J. Immunol. Res."},{"key":"2021113012313212400_B6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fphys.2017.00519","article-title":"NLRP3 inflammasome as a molecular marker in diabetic cardiomyopathy","volume":"8","author":"Luo","year":"2017","journal-title":"Front. Physiol."},{"key":"2021113012313212400_B7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"2021113012313212400_B8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"},{"key":"2021113012313212400_B9","first-page":"109","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol. Rev."},{"key":"2021113012313212400_B10","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/bph.12959","article-title":"The cGMP\/PKG pathway as a common mediator of cardioprotection: translatability and mechanism","volume":"172","author":"Inserte","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"2021113012313212400_B11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12933-015-0309-x","article-title":"The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus","volume":"14","author":"Matyas","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113012313212400_B12","doi-asserted-by":"publisher","first-page":"H281","DOI":"10.1152\/ajpheart.00666.2014","article-title":"Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms","volume":"308","author":"Shi","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113012313212400_B13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.bbadis.2017.11.023","article-title":"Melatonin protects diabetic heart against ischemia-reperfusion injury, role of membrane receptor-dependent cGMP-PKG activation","volume":"1864","author":"Yu","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113012313212400_B14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","article-title":"Glucose control by the kidney: an emerging target in diabetes","volume":"53","author":"Marsenic","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"2021113012313212400_B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"2021113012313212400_B16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2021113012313212400_B17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00125-016-4194-y","article-title":"The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects","volume":"60","author":"Vettor","year":"2017","journal-title":"Diabetologia"},{"key":"2021113012313212400_B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113012313212400_B19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","article-title":"Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes","volume":"31","author":"Hammoudi","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2021113012313212400_B20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol."},{"key":"2021113012313212400_B21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"2021113012313212400_B22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113012313212400_B23","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","article-title":"Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects","volume":"8","author":"Andreadou","year":"2017","journal-title":"Front. Physiol."},{"key":"2021113012313212400_B24","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1159\/000475942","article-title":"The sodium-glucose co-transporter 2 inhibitor, empagliflozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway","volume":"41","author":"Zhou","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"2021113012313212400_B25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113012313212400_B26","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1681\/ASN.2016070811","article-title":"(Pro)renin receptor is an amplifier of Wnt\/beta-catenin signaling in kidney injury and fibrosis","volume":"28","author":"Li","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113012313212400_B27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.bbrc.2018.08.204","article-title":"RhoA protects the podocytes against high glucose-induced apoptosis through YAP and plays critical role in diabetic nephropathy","volume":"504","author":"Huang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113012313212400_B28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvu072","article-title":"Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction","volume":"103","author":"Fan","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"2021113012313212400_B29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1253\/circj.CJ-13-1187","article-title":"Production of reactive oxygen species in the diabetic heart. Roles of mitochondria and NADPH oxidase","volume":"78","author":"Teshima","year":"2014","journal-title":"Circ J."},{"key":"2021113012313212400_B30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/1753-0407.12239","article-title":"Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: a cross-sectional comparison with non-diabetic weight-matched controls","volume":"7","author":"Ofstad","year":"2015","journal-title":"J. Diabetes"},{"key":"2021113012313212400_B31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1210\/er.2003-0012","article-title":"Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications","volume":"25","author":"Fang","year":"2004","journal-title":"Endocr. Rev."},{"key":"2021113012313212400_B32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"2021113012313212400_B33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1253\/circj.CJ-16-1148","article-title":"Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease- results from EMPA-REG OUTCOME((R))","volume":"81","author":"Kaku","year":"2017","journal-title":"Circ. J."},{"key":"2021113012313212400_B34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113012313212400_B35","first-page":"233","article-title":"Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes","volume":"31","author":"Hammoudi","year":"2017"},{"key":"2021113012313212400_B36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11897-013-0166-4","article-title":"Ventricular remodeling in heart failure with preserved ejection fraction","volume":"10","author":"Shah","year":"2013","journal-title":"Curr. Heart Fail. Rep."},{"key":"2021113012313212400_B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies","volume":"128","author":"Bernardo","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"2021113012313212400_B38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1530\/JOE-17-0681","article-title":"Isosteviol ameliorates diabetic cardiomyopathy in rats by inhibiting ERK and NF-kappaB signaling pathways","volume":"238","author":"Tang","year":"2018","journal-title":"J. Endocrinol."},{"key":"2021113012313212400_B39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.diabres.2017.08.018","article-title":"Transforming growth factor beta (TGF-beta) mediates cardiac fibrosis and induces diabetic cardiomyopathy","volume":"133","author":"Yue","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2021113012313212400_B40","doi-asserted-by":"publisher","first-page":"25234","DOI":"10.3390\/ijms161025234","article-title":"Diabetic cardiovascular disease induced by oxidative stress","volume":"16","author":"Kayama","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"2021113012313212400_B41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.fct.2013.11.013","article-title":"Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis","volume":"63","author":"Sun","year":"2014","journal-title":"Food Chem. Toxicol."},{"key":"2021113012313212400_B42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113012313212400_B43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat. Immunol."},{"key":"2021113012313212400_B44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with Saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2021113012313212400_B45","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bbrc.2015.05.042","article-title":"Palmitate promotes autophagy and apoptosis through ROS-dependent JNK and p38 MAPK","volume":"463","author":"Liu","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113012313212400_B46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mito.2015.04.004","article-title":"Mitochondrial Lon protease controls ROS-dependent apoptosis in cardiomyocyte under hypoxia","volume":"23","author":"Kuo","year":"2015","journal-title":"Mitochondrion"},{"key":"2021113012313212400_B47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1475-2840-12-158","article-title":"Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy","volume":"12","author":"Liu","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113012313212400_B48","doi-asserted-by":"publisher","first-page":"e13741","DOI":"10.14814\/phy2.13741","article-title":"Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts","volume":"6","author":"Mizuno","year":"2018","journal-title":"Physiol. Rep."},{"key":"2021113012313212400_B49","doi-asserted-by":"publisher","first-page":"H2075","DOI":"10.1152\/ajpheart.00521.2009","article-title":"Expression of constitutively active cGMP-dependent protein kinase inhibits glucose-induced vascular smooth muscle cell proliferation","volume":"297","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113012313212400_B50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"2021113012313212400_B51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fimmu.2015.00153","article-title":"KCa3.1\/IK1 channel regulation by cGMP-dependent protein kinase (PKG) via reactive oxygen species and CaMKII in microglia: an immune modulating feedback system?","volume":"6","author":"Ferreira","year":"2015","journal-title":"Front. Immunol."},{"key":"2021113012313212400_B52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"2021113012313212400_B53","doi-asserted-by":"publisher","first-page":"7670854","DOI":"10.1155\/2019\/7670854","article-title":"Naringenin attenuates myocardial ischemia-reperfusion injury via cGMP-PKGIalpha signaling and in vivo and in vitro studies","volume":"2019","author":"Yu","year":"2019","journal-title":"Oxid. Med. Cell Longev."},{"key":"2021113012313212400_B54","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.bbadis.2017.11.023","article-title":"Melatonin protects diabetic heart against ischemia-reperfusion injury, role of membrane receptor-dependent cGMP-PKG activation","volume":"1864","author":"Yu","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2021113012313212400_B55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"2021113012313212400_B56","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"2021113012313212400_B57","doi-asserted-by":"publisher","first-page":"14872","DOI":"10.1038\/s41598-018-33293-2","article-title":"Empagliflozin ammeliorates high glucose induced-cardiac dysfuntion in human iPSC-derived cardiomyocytes","volume":"8","author":"Ng","year":"2018","journal-title":"Sci. Rep."},{"key":"2021113012313212400_B58","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"2021113012313212400_B59","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/133\/15\/1705\/845435\/cs-2019-0585.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/133\/15\/1705\/845435\/cs-2019-0585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T07:32:57Z","timestamp":1638257577000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/133\/15\/1705\/219065\/Empagliflozin-prevents-cardiomyopathy-via-sGC-cGMP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":59,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20190585","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8]]}}}